<DOC>
	<DOCNO>NCT00001450</DOCNO>
	<brief_summary>This Phase II study paclitaxel ( Taxol R ) administer 96-hour ( 4 day ) continuous infusion follow bolus cisplatin previously untreated patient stage III/IV relapse non-small cell lung cancer ( NSCLC ) . The goal phase II study determine response rate infusional paclitaxel bolus cisplatin regimen patient advance NSCLC .</brief_summary>
	<brief_title>Phase II Trial 96-Hour Continuous Infusion Paclitaxel Followed Cisplatin Patients With Stage III/IV Relapsed NSCLC</brief_title>
	<detailed_description>This Phase II study paclitaxel ( Taxol R ) administer 96-hour ( 4 day ) continuous infusion follow bolus cisplatin previously untreated patient stage III/IV relapse non-small cell lung cancer ( NSCLC ) . The goal phase II study determine response rate infusional paclitaxel bolus cisplatin regimen patient advance NSCLC . In addition , plasma level paclitaxel measure , vitro paclitaxel chemosensitivity tumor cell many patient possible determine . This allow study relationship vitro drug sensitivity , achievable plasma concentration paclitaxel , patient ' response therapy .</detailed_description>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm nonsmall cell lung cancer , include : Squamous cell carcinoma , Adenocarcinoma , Large cell carcinoma , Mixed histologies absence predominant small cell component . Eligible Stages Include : Stage IV , Stage IIIA/B ineligible resection radiotherapy , Postsurgical recurrence histologically cytologically proven . CNS Metastases Allowed Provided : Radiotherapy complete prior entry . No requirement concurrent steroid . No carcinomatous meningitis . No epidural metastasis . Measurable disease require . PRIOR/CONCURRENT THERAPY : Biologic Therapy : Not specify . Chemotherapy : No prior chemotherapy lung cancer . Endocrine Therapy : Not specify . Radiotherapy : No prior chest irradiation lung cancer . Surgery : Prior surgery allow . PATIENT CHARACTERISTICS : Age : 18 . Performance Status : ECOG 02 . Hematopoietic : Absolute granulocyte count great 2,000 . Platelet count great 100,000 . Hepatic : Bilirubin great 1.5 mg/dL . Renal : Creatinine great 1.5 mg/dL . Cardiovascular : No CHF unless fully compensate . No second thirddegree heart block . No uncontrolled , symptomatic atrial dysrhythmia except sinus bradycardia . No sustained ventricular tachycardia . No MI within 3 month . OTHER : No uncontrolled infection unless due obstruct bronchus . No major psychiatric problem require hospitalization . No psychotropic medication phenothiazine . No contraindication transfusion , require . No second malignancy within 5 year except : Nonmelanomatous skin cancer . In situ cervical cancer . No pregnant nursing woman . Effective contraception require fertile patient .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 1999</verification_date>
	<keyword>Chemotherapy</keyword>
	<keyword>In Vitro Testing</keyword>
	<keyword>Infusional</keyword>
	<keyword>Lung Neoplasm</keyword>
	<keyword>Pharmacokinetics</keyword>
</DOC>